Path integral molecular dynamics

Integral Molecular Launches TiterSafe™ Influenza Virus-Like Particles for Safe and Convenient Vaccine Testing

Retrieved on: 
星期二, 十一月 7, 2023
FDA, Neuraminidase, HA, SARS-CoV-2, RNA, Architecture, Infection, Research, Virus, Biodegradable additives, NA, Serum, Path integral molecular dynamics, Influenza, Fever Dream, DNA, Vaccine, Zika fever

PHILADELPHIA, Nov. 7, 2023 /PRNewswire/ -- Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles , an off-the-shelf virus-alternative for key experiments in testing influenza vaccines.

Key Points: 
  • PHILADELPHIA, Nov. 7, 2023 /PRNewswire/ -- Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles , an off-the-shelf virus-alternative for key experiments in testing influenza vaccines.
  • In contrast, traditional assays require the difficult preparation of live influenza virus, potentially expose researchers to infection, and need dedicated containment facilities for pandemic virus strains.
  • TiterSafe particles mimic the architecture of live virus, featuring surface influenza proteins hemagglutinin (HA) and neuraminidase (NA) along with an interior protein core.
  • Inhibition of this clumping by anti-HA antibodies in serum (an "HAI assay") is the standard FDA-accepted method for influenza vaccine assessment.

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

Retrieved on: 
星期二, 十月 31, 2023
IND, CD3, Lehr, Context, CLDN6, SITC, Immunotherapy, Annual general meeting, Benchmarking, Path integral molecular dynamics, Society, Patient, Drug discovery, Toxicity, Abstract, Fine chemical, Pharmaceutical industry

PHILADELPHIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced encouraging preclinical data regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.

Key Points: 
  • PHILADELPHIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced encouraging preclinical data regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.
  • Findings from Context’s research team, in conjunction with development partner Integral Molecular, illustrate the potential of CTIM-76 to treat CLDN6-positive tumors.
  • Notably:
    CTIM-76 was shown to have high potency and target selectivity in both binding and cytotoxicity assays.
  • “The preclinical data at this year's SITC meeting will illustrate the potential of CTIM-76 to target CLDN6,” said Lehr.

Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma

Retrieved on: 
星期五, 十一月 3, 2023
Membrane, CD3, GPCR, RNA, Society for Immunotherapy of Cancer, GPRC5D, Doctor of Philosophy, Poster, Chicken, SITC, Immunotherapy, MPS, Antibody, Path integral molecular dynamics, Virus-like particle, Society, Patient, Integral, BCMA, DNA, Fine chemical, Vaccine

Recent clinical data demonstrate that combination therapy of T cell engaging molecules individually targeting GPRC5D and BCMA on tumor cells offers unprecedented therapeutic benefits in relapsed/refractory multiple myeloma patients.

Key Points: 
  • Recent clinical data demonstrate that combination therapy of T cell engaging molecules individually targeting GPRC5D and BCMA on tumor cells offers unprecedented therapeutic benefits in relapsed/refractory multiple myeloma patients.
  • A trispecific antibody that simultaneously engages these molecules while activating T cells is expected to provide comparable and additional benefits as a monotherapy.
  • Integral Molecular's oncology drug discovery program has yielded a panel of high affinity bispecific and trispecific molecules targeting GPRC5D, a GPCR target with complex structural biology.
  • GPRC5D and other antibody assets from Integral Molecular are available for licensing.

Integral Molecular Secures Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets

Retrieved on: 
星期四, 十月 5, 2023
Disease, Membrane, Health, Cancer, Antibody, Doctor of Philosophy, Integral, RNA, Multiple myeloma, SITC, Path integral molecular dynamics, GPRC5D, Primate, Virus-like particle, MPS, Eurosport 1, G protein-coupled receptor, Research, NIH, Chicken, Vaccine

Funding awarded by NIH enables Integral Molecular to discover antibodies against many of these targets.

Key Points: 
  • Funding awarded by NIH enables Integral Molecular to discover antibodies against many of these targets.
  • To enable better models of human disease, Integral Molecular has also received NIH funding to discover antibodies that target highly conserved proteins across species.
  • Integral Molecular will employ its MPS antibody discovery platform to discover antibodies for both initiatives.
  • Integral Molecular's strategy of generating antibodies in chickens is key for producing antibodies against conserved targets, a feat not easily achieved with conventional technologies.

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Retrieved on: 
星期三, 八月 9, 2023
Insurance, Cell death, CD3, Path integral molecular dynamics, Research, CLDN6, Immunotherapy, Lung, Context, IND, Society, Conference, Cryptocurrency, Pharmaceutical industry, Vaccine, Rare-earth element

PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming business highlights.

Key Points: 
  • Cash and cash equivalents of $25.1 million as of June 30, 2023
    PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming business highlights.
  • “During the second quarter of this year, Context continued development of our preclinical asset CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody.
  • General and administrative expenses were $1.8 million for the second quarter 2023, as compared to $2.0 million for the same period in 2022.
  • Context reported a net loss of $5.0 million for the second quarter 2023, as compared to $4.0 million for the same period in 2022.

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

Retrieved on: 
星期三, 五月 10, 2023
Diamond, AACR, Cell death, CD3, Neoplasm, Clinical trial, Cancer, Path integral molecular dynamics, American Association for Cancer Research, G&A, Research, CLDN6, Immunotherapy, Lung, Investigational New Drug, Patient, Context, R, IND, Conference, Cryptocurrency, Life insurance

PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced its financial results for the first quarter ended March 31, 2023, and reported on recent and upcoming business highlights.

Key Points: 
  • In April 2023, participated in the Diamond Equity Emerging Growth Invitational Investor Conference and the 22nd Annual Needham Virtual Healthcare Conference.
  • Research and development (R&D) expenses were $4.5 million for first quarter 2023, as compared to $1.4 million for the same period in 2022.
  • General and administrative (G&A) expenses were $2.1 million for both the first quarter 2023 and the first quarter 2022.
  • Context reported a net loss of $6.3 million for the first quarter 2023, as compared to $3.4 million for the same period in 2022.

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Retrieved on: 
星期三, 三月 22, 2023
Insurance, AACR, Liver function tests, CD3, Survival, Lonza, Clinical trial, LFT, Path integral molecular dynamics, Anastrozole, G&A, Research, CLDN6, Immunotherapy, Lung, American Association for Cancer Research, Patient, Immune system, Cancer, Context, Growth, R, IND, Female, Breast cancer, Pharmaceutical industry, Cryptocurrency, Vaccine, Fine chemical

PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022. Additionally, the Company announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway into late 2024. The resulting changes include discontinuing the development of onapristone extended release (ONA-XR) and focusing on the development of CTIM-76, its Claudin 6 (CLDN6) bispecific antibody clinical candidate.

Key Points: 
  • PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022.
  • “We are shifting our development focus to our compelling preclinical asset CTIM-76, a CLDN6 x CD3 bispecific antibody.
  • ET, Context will host an investor R&D webinar with the Company’s management team and AACR presenter to discuss the presentation.
  • Context reported a net loss of $14.8 million for 2022, as compared to $10.5 million for the same period in 2021.

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Retrieved on: 
星期二, 十一月 29, 2022
Path integral molecular dynamics, Monoclonal antibody, CD3, Antibody, Food, Endometrial cancer, Cancer, Risk, Female, Context, Therapy, Patient safety, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, FV, Integral, CLDN6, FC, Immunoglobulin G, Ovarian cancer, Breast, Pharmaceutical industry, Vaccine, IND

PHILADELPHIA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today announced the selection of CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers, resulting from its research collaboration and licensing agreement with Integral Molecular.

Key Points: 
  • With the potential to reach a large patient population and selective expression on cancer cells, CLDN6 has emerged as an exciting drug target.
  • This year has been marked by several exciting and significant milestones for Context, culminating in naming our lead CLDN6 clinical development candidate, CTIM-76, a bispecific antibody showing high selectivity for CLDN6, said Martin Lehr, CEO of Context Therapeutics.
  • The Companys pipeline includes small molecule and bispecific antibody drug candidates that target cancer signaling pathways.
  • Context is also developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development.

Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness

Retrieved on: 
星期四, 十月 20, 2022
Influenza, Omicron, Therapy, Fever Dream, Virus, Vaccine, Laboratory, Severe acute respiratory syndrome coronavirus 2, Antibody, RVP, Research, Collection, Path integral molecular dynamics, Cancer, BSL4, Reporter virus particles, Doctor of Philosophy, Industry, Virology, BSL2, Diabetes, Membrane protein, COVID-19, Degenerative disease, Zika fever

Integral Molecular's new RVP offerings feature influenza A H5N1, Ebola virus, and Marburg virus.

Key Points: 
  • Integral Molecular's new RVP offerings feature influenza A H5N1, Ebola virus, and Marburg virus.
  • Integral Molecular has also created custom variants, as well as thousands of mutations in this safe RVP format to enable prediction of viral escape and the creation of better vaccines.
  • "With 20 years of experience studying viruses and vaccines, we are excited to launch new products that enable faster and safer vaccine development against the world's deadliest viruses," said Sharon Willis, PhD, co-founder of Integral Molecular.
  • Integral Molecular's broad range of RVPs also includes a selection of influenza A and B seasonal strains, dengue, Zika, and chikungunya viruses.

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

Retrieved on: 
星期二, 九月 27, 2022
PR, Bispecific monoclonal antibody, Breast, Path integral molecular dynamics, Granulosa cell tumour, Woman, Twitter, Lehr, Food, IND, Intention, LinkedIn, Company, MBCA, Private Securities Litigation Reform Act, Context, Therapy, Forward-looking statement, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, Cancer, U.S. Securities and Exchange Commission, Breast cancer, CEO, Endometrial cancer, Female, CLDN6, Nasdaq, Climate, SERD, New Drug Application, Biotechnology, GLOBE, CD3, Pharmaceutical industry

PHILADELPHIA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing novel treatments for breast and gynecological cancers,today announced updated cash guidance to extend its runway into Q1 2024.

Key Points: 
  • PHILADELPHIA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing novel treatments for breast and gynecological cancers,today announced updated cash guidance to extend its runway into Q1 2024.
  • Context has been fortunate to collaborate with two tremendous organizations The Menarini Group and Integral Molecular.
  • Context Therapeutics Inc. (Nasdaq: CNTX)is a clinical-stage biopharmaceutical company committed to advancing medicines for female cancers.
  • Context is also developing a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development.